Your browser doesn't support javascript.
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
Alexander, James L; Moran, Gordon W; Gaya, Daniel R; Raine, Tim; Hart, Ailsa; Kennedy, Nicholas A; Lindsay, James O; MacDonald, Jonathan; Segal, Jonathan P; Sebastian, Shaji; Selinger, Christian P; Parkes, Miles; Smith, Philip J; Dhar, Anjan; Subramanian, Sreedhar; Arasaradnam, Ramesh; Lamb, Christopher A; Ahmad, Tariq; Lees, Charlie W; Dobson, Liz; Wakeman, Ruth; Iqbal, Tariq H; Arnott, Ian; Powell, Nick.
  • Alexander JL; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
  • Moran GW; NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals and The University of Nottingham, Nottingham, UK.
  • Gaya DR; Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK; Department of Medicine, University of Glasgow, Glasgow, UK.
  • Raine T; Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Hart A; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, St Mark's Hospital, London, UK.
  • Kennedy NA; Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group University of Exeter, Exeter, UK.
  • Lindsay JO; Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK; Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • MacDonald J; Department of Medicine, University of Glasgow, Glasgow, UK; Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Segal JP; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, The Hillingdon Hospitals NHS Foundation Trust, Uxbridge, UK.
  • Sebastian S; IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • Selinger CP; Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Parkes M; Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Smith PJ; Department of Gastroenterology, Liverpool University Hospitals NHS Foundation Trusts, Liverpool, UK.
  • Dhar A; Department of Gastroenterology, County Durham & Darlington NHS Foundation Trust, Durham, UK.
  • Subramanian S; Department of Gastroenterology, Liverpool University Hospitals NHS Foundation Trusts, Liverpool, UK.
  • Arasaradnam R; Department of Gastroenterology, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK.
  • Lamb CA; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Ahmad T; Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group University of Exeter, Exeter, UK.
  • Lees CW; Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Gastroenterology, Western General Hospital, Edinburgh, UK.
  • Dobson L; IBD Registry Limited, London, UK.
  • Wakeman R; Crohn's & Colitis UK, Hatfield, UK.
  • Iqbal TH; Institute of Translational Medicine, University of Birmingham, Birmingham, UK; Department of Gastroenterology, University Hospitals Birmingham, Birmingham, UK.
  • Arnott I; Department of Gastroenterology, Western General Hospital, Edinburgh, UK.
  • Powell N; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: nicholas.powell@imperial.ac.uk.
Lancet Gastroenterol Hepatol ; 6(3): 218-224, 2021 03.
Artículo en Inglés | MEDLINE | ID: covidwho-1195586
ABSTRACT
SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Humanos País/Región como asunto: Europa Idioma: Inglés Revista: Lancet Gastroenterol Hepatol Año: 2021 Tipo del documento: Artículo País de afiliación: S2468-1253(21)00024-8

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Humanos País/Región como asunto: Europa Idioma: Inglés Revista: Lancet Gastroenterol Hepatol Año: 2021 Tipo del documento: Artículo País de afiliación: S2468-1253(21)00024-8